Literature DB >> 28081595

Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?

Byung-Cheol Song1.   

Abstract

Entities:  

Keywords:  Adefovir; Chronic hepatitis B; Lamivudine resistance; Suboptimal response; Tenofovir

Mesh：

Substances：

Year:  2016        PMID： 28081595      PMCID： PMC5266348          DOI： 10.3350/cmh.2016.0108

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN： 2287-2728


× No keyword cloud information.
  33 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

3.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

5.  Durability of serologic response after lamivudine treatment of chronic hepatitis B.

Authors:  Jules L Dienstag; Janusz Cianciara; Selim Karayalcin; Kris V Kowdley; Bernard Willems; Stanilav Plisek; Mary Woessner; Stephen Gardner; Eugene Schiff
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B.

Authors:  Eugene R Schiff; Samuel S Lee; You-Chen Chao; Seung Kew Yoon; Fernando Bessone; Shun-Sheng Wu; Wieslaw Kryczka; Yoav Lurie; Adrian Gadano; George Kitis; Suzanne Beebe; Dong Xu; Hong Tang; Uchenna Iloeje
Journal:  Clin Gastroenterol Hepatol       Date:  2010-12-08       Impact factor: 11.382

7.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.

Authors:  Young-Suk Lim; Byung Chul Yoo; Kwan Soo Byun; So Young Kwon; Yoon Jun Kim; Jihyun An; Han Chu Lee; Yung Sang Lee
Journal:  Gut       Date:  2015-03-23       Impact factor: 23.059

8.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Christy Wing-Hin Mak; Stanley King-Yeung Lee; Zoe Man-Yi Ip; Andrew Ting-Ho Lam; Henry Wing-Hang Iu; Joyce May-Sum Leung; Jennifer Wing-Yan Lai; Angeline Oi-Shan Lo; Hoi-Yun Chan; Vincent Wai-Sun Wong
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

9.  Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Yoo-Kyung Cho; Xiu-Ji Cui; Seung Uk Jeong; Byung-Cheol Song
Journal:  Antiviral Res       Date:  2014-10-07       Impact factor: 5.970

10.  Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.

Authors:  Jung Gil Park; Soo Young Park
Journal:  Clin Mol Hepatol       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.